Investigational drug · Phase 2
RO7247669
Also called: Tobemstomig, RG6139, PD1-LAG3 BsAb
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
6
3 still active
All registered trials
9
Any phase or sponsor naming "RO7247669"
First trial start
2019
Nov 11, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RO7247669", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumors
- Metastatic Melanoma
- Non-small Cell Lung Cancer
- Esophageal Squamous Cell Carcinoma
- Advanced Liver Cancers
- Urothelial Cancer
- Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Breast Cancer
- Renal Cell Carcinoma
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Melanoma · Kidney cancer (renal cell carcinoma) · Stomach and esophageal cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "RO7247669" as an intervention, largest first.
- A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial CancerPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05645692 · 204 participants · Start Apr 13, 2023 · Primary completion Dec 31, 2026
Drug: Atezolizumab; Tobemstomig and 1 more · For: Urothelial Cancer
Sites: Cleveland, Ohio; Houston, Texas; Macquarie Park, Australia · 56 sites in all
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05805501 · 199 participants · Start Apr 21, 2023 · Primary completion Oct 5, 2026
Drug: Tobemstomig; Tiragolumab and 2 more · For: Renal Cell Carcinoma
Sites: Birmingham, Alabama; Orange, California; Atlanta, Georgia · 42 sites in all
- A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the EsophagusPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04785820 · 190 participants · Start Jun 25, 2021 · Primary completion Jan 30, 2025
Drug: Lomvastomig; Tobemstomig and 1 more · For: Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Sites: Buenos Aires, Argentina; La Rioja, Argentina; Porto Alegre, Brazil · 52 sites in all
- A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05775289 · 182 participants · Start Mar 15, 2023 · Primary completion Jun 20, 2024
Drug: Tobemstomig; Pembrolizumab and 3 more · For: Non-small Cell Lung Cancer
Sites: Detroit, Michigan; Reno, Nevada; Westmead, Australia · 50 sites in all
- Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid TumorsActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04140500 · 170 participants · Start Nov 11, 2019 · Primary completion Jun 30, 2027
Drug: RO7247669 · For: Solid Tumors; Metastatic Melanoma; Non-small Cell Lung Cancer and 1 more
Sites: København Ø, Denmark; Odense C, Denmark; Tbilisi, Georgia · 25 sites in all
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05116202 · 110 participants · Start Feb 2, 2022 · Primary completion Sep 22, 2023
Drug: Nivolumab; Ipilimumab and 4 more · For: Melanoma
Sites: Duarte, California; Los Angeles, California; Tampa, Florida · 14 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05419388 · 93 participants · Start Aug 15, 2022 · Primary completion May 1, 2024
Drug: RO7247669 · For: Melanoma
Sites: Coffs Harbour, Australia; North Sydney, Australia; Woolloongabba, Australia · 22 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05852691 · 83 participants · Start Jul 18, 2023 · Primary completion Oct 15, 2026
Drug: Tobemstomig; Pembrolizumab and 1 more · For: Breast Cancer
Sites: Los Alamitos, California; New York, New York; Charlotte, North Carolina · 36 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05908786 · 62 participants · Start Dec 5, 2023 · Primary completion Aug 27, 2025
Drug: Atezolizumab; Bevacizumab and 2 more · For: Carcinoma, Hepatocellular
Sites: Los Angeles, California; Santa Monica, California; Washington D.C., District of Columbia · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A randomised, open-label, phase II study of tobemstomig combinations in patients with previously untreated advanced clear-cell renal cell carcinoma.
Rini BI, Powles T, Tomczak P, et al. · ESMO Open 2026
- A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus.
Wyrwicz L, Dechaphunkul A, Lee JS, et al. · Clin Cancer Res 2026
- Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control.
Weber PAA, Perro M, Nicolini VG, et al. · Cancer Res Commun 2026
- A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.
Garralda E, Markert C, Moreno V, et al. · Clin Cancer Res 2026
- LAG-3 antagonists for cancer treatment: an updated patent review (2020-2025).
Pérez-Santos M, Landeta G, Anaya-Ruiz M, et al. · Expert Opin Ther Pat 2026
- Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.
Long GV, Nair N, Marbach D, et al. · Nat Med 2025
Also in development for Solid Tumors
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- DivarasibGDC-6036, RO7435846Phase 38 trials
Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.